A Phase 1, Randomized, Open Label, Partial Crossover Study To Evaluate The Pharmacokinetics (PK) And Safety Of Three Modified Release (MR) And One Immediate Release (IR) Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2012
At a glance
- Drugs Tofacitinib (Primary)
- Indications Inflammatory bowel diseases; Psoriasis; Rheumatic disorders; Transplant rejection
- Focus Pharmacokinetics
- Sponsors Pfizer
- 11 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Dec 2011 New trial record